Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide

Rhea-AI Summary

Labcorp (NYSE: LH) and Children's Hospital of Philadelphia announced a strategic collaboration on April 13, 2026 to speed discovery, development and national availability of specialized pediatric diagnostics.

The partnership creates a joint pediatric diagnostics innovation pipeline to develop age-appropriate tests across oncology, metabolic disease, autoimmune conditions and rare disorders and to expand nationwide access through Labcorp's laboratory network.

News Market Reaction – LH

+1.25%

+1.25% Session close to close

In the Apr 13 session, LH gained 1.25%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a strategic push into specialized pediatric diagnostics through collabo...

Analysis

This announcement highlights a strategic push into specialized pediatric diagnostics through collaboration with CHOP, leveraging Labcorp’s national infrastructure and commercialization capabilities. It adds to a series of partnerships in oncology and digital pathology and follows solid 2025 financial performance with adjusted EPS of $16.44. Investors may focus on how quickly the joint innovation pipeline yields commercially available tests and how this complements guidance for 2026 revenue and earnings.

Historical Context

5 past events · Latest: Apr 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 09	Dividend declaration	Positive	-0.5%	Announced quarterly cash dividend of $0.72 per share with set record date.
Mar 31	Earnings date set	Neutral	+2.2%	Scheduled Q1 2026 earnings release and webcast with replay details.
Mar 18	Oncology collaboration	Positive	-1.8%	Expanded Illumina collaboration to broaden access to precision oncology testing.
Feb 23	Digital pathology deal	Positive	+0.9%	Expanded PathAI partnership to deploy FDA-cleared AISight Dx nationwide.
Feb 17	Earnings and guidance	Positive	-2.1%	Reported 2025 growth, higher adjusted EPS and issued 2026 revenue/EPS guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive strategic and financial announcements have often seen mixed or negative next-day reactions, with 3 divergences versus 2 alignments in the last five events.

Recent Company History

Over recent months, Labcorp reported strong 2025 results, with Q4 revenue of $3.52B and full-year revenue of $13.95B, alongside adjusted EPS of $16.44 and 2026 guidance issued on Feb 17. It has pursued multiple collaborations, including expansions with PathAI on Feb 23 and Illumina on Mar 18, and declared a $0.72 dividend on Apr 9. Today’s CHOP collaboration continues this strategy of partnerships to broaden advanced diagnostics access.

Key Terms

pediatric diagnostics, oncology, metabolic disease, autoimmune conditions, +3 more

7 terms

pediatric diagnostics medical

"Collaboration aims to speed the discovery, development and national availability of specialized pediatric diagnostics"

Pediatric diagnostics are medical tests, tools and procedures specifically designed to detect, monitor or rule out diseases and conditions in infants, children and adolescents. For investors, they matter because childhood-focused tests often require different technology, regulation and clinical validation than adult products, creating distinct market opportunities and risks; think of it as a specialized toolkit made for smaller, more delicate engines that can affect adoption, reimbursement and long-term sales.

oncology medical

"The collaboration will make novel diagnostics available nationwide across key clinical areas, such as oncology, metabolic disease and autoimmune conditions."

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

metabolic disease medical

"available nationwide across key clinical areas, such as oncology, metabolic disease and autoimmune conditions."

A metabolic disease is a disorder that disrupts the body’s normal chemical processes for turning food into energy and maintaining balance, like when an engine or fuel system in a car isn’t working right. Investors care because these conditions drive demand for diagnostics, medicines, devices and long‑term care, shape regulatory and reimbursement decisions, and create predictable market opportunities or costs that affect company revenue and research priorities.

autoimmune conditions medical

"available nationwide across key clinical areas, such as oncology, metabolic disease and autoimmune conditions."

Autoimmune conditions are illnesses in which the body's immune system mistakenly attacks healthy tissues, causing chronic inflammation, damage, or organ dysfunction — like a home security system that starts targeting the house itself. For investors, these conditions matter because they create sustained demand for diagnostics, drugs, and medical services, affect clinical trial design and regulatory decisions, and can represent both revenue opportunities and scientific or reimbursement risks for healthcare companies.

genetics medical

"bringing breakthrough diagnostics in cancer, genetics, immune disorders and rare diseases to patients sooner"

The study of genes and how biological traits are passed from one generation to the next; think of genes as an instruction manual inside cells that helps determine characteristics and disease risk. For investors, genetics matters because discoveries or tests can create new drugs, diagnostic tools, or treatments, change the size of addressable patient populations, affect regulatory hurdles and patents, and therefore influence a company’s future revenue and risk profile.

immune disorders medical

"bringing breakthrough diagnostics in cancer, genetics, immune disorders and rare diseases to patients sooner"

Immune disorders are conditions in which the body's defense system either attacks healthy tissues or fails to protect against infections, like a security team that is overzealous or absent. For investors, they matter because they define the need for medicines, diagnostic tests and long-term care, influencing drug development pipelines, clinical trial risk and potential market size for companies working on treatments or diagnostics.

rare diseases medical

"bringing breakthrough diagnostics in cancer, genetics, immune disorders and rare diseases to patients sooner"

Medical conditions that affect a very small percentage of the population, often chronic, serious, and with limited or no approved treatments. For investors, rare diseases are like niche markets: patient groups are small but demand can be intense, allowing higher prices, quicker regulatory pathways, and exclusive rights that can drive significant returns—while also carrying development, reimbursement, and commercial risks tied to that small customer base.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Collaboration aims to speed the discovery, development and national availability of specialized pediatric diagnostics

BURLINGTON, N.C. and PHILADELPHIA, April 13, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Children's Hospital of Philadelphia (CHOP), the nation's first pediatric hospital, announced today a strategic collaboration to accelerate the discovery, development and nationwide availability of specialized pediatric diagnostics. By combining CHOP's pediatric research and clinical expertise with Labcorp's national diagnostic infrastructure, scientific capabilities and commercialization expertise, the collaboration aims to expand access to advanced diagnostic testing for children and families across the country.

"Our shared aim to improve children's health makes this collaboration so powerful," said Stephen R. Master, M.D., Ph.D., division chief and director of metabolic and advanced diagnostics at Children's Hospital of Philadelphia. "By pairing CHOP's pediatric leadership with Labcorp's nationwide reach, we seek to deliver important new and specialized tests to children and their families more efficiently and at greater scale."

Innovation Pipeline to Advance Pediatric Diagnostic Development
At the core of the collaboration is the creation of a joint pediatric diagnostics innovation pipeline where CHOP and Labcorp will team up to identify, develop and expand new tests and technologies with a goal of streamlining the path from discovery to national availability. Pediatric-specific diagnostics deliver more accurate, age-appropriate insights for children by accounting for their unique biology, developmental stages and physiological ranges—factors that traditional adult-oriented tests often overlook. The collaboration will make novel diagnostics available nationwide across key clinical areas, such as oncology, metabolic disease and autoimmune conditions.

Expanding Nationwide Access to Advanced Pediatric Testing
Together, the organizations will provide clinicians and health systems with cutting-edge pediatric testing—bringing breakthrough diagnostics in cancer, genetics, immune disorders and rare diseases to patients sooner and enabling earlier, more precise diagnoses.

"Labcorp and CHOP share a commitment to advancing pediatric care. By combining CHOP's deep pediatric expertise with Labcorp's scientific capabilities and national reach, we can bring pediatric diagnostic innovations to patients faster and make advanced testing accessible to many more families," said Bryan Vaughn, executive vice president, Diagnostics at Labcorp.

"Today's announcement marks an important milestone at the intersection of scientific research and collaboration," said Joseph Mitchell, M.D., president at Children's Hospital of Philadelphia. "Our commitment to innovation has always been driven by one goal: improving the lives of children. By working closely with Labcorp, we can create the breakthroughs that children and families need – today and in the years to come."

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com

About Children's Hospital of Philadelphia 
A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center), and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit https://www.chop.edu.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the collaboration between Labcorp and Children's Hospital of Philadelphia.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond Labcorp's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement its business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in Labcorp's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/childrens-hospital-of-philadelphia-and-labcorp-announce-a-collaboration-to-accelerate-access-to-advanced-pediatric-diagnostics-nationwide-302740400.html

SOURCE Labcorp

FAQ

What did Labcorp (LH) and Children's Hospital of Philadelphia announce on April 13, 2026?

They announced a strategic collaboration to accelerate pediatric diagnostic development and nationwide availability. According to Labcorp, the partnership creates a joint innovation pipeline to identify, develop and scale pediatric-specific tests across oncology, metabolic disease, immune disorders and rare conditions.

How will the Labcorp (LH) and CHOP collaboration affect access to pediatric testing?

It aims to expand nationwide access to advanced pediatric testing through Labcorp's national infrastructure. According to Labcorp, combining CHOP's pediatric expertise with Labcorp's lab network should make specialized tests more widely available to clinicians and families.

Which pediatric clinical areas will Labcorp (LH) and CHOP focus on together?

The collaboration targets oncology, metabolic disease, autoimmune conditions and rare genetic disorders. According to Labcorp, those areas were highlighted as priority clinical domains for developing age-appropriate diagnostics and streamlining national deployment of new tests.

What is the role of the joint pediatric diagnostics innovation pipeline with Labcorp (LH)?

The pipeline will identify, develop and scale new pediatric tests from discovery to national availability. According to Labcorp, the goal is to streamline the path from research to commercial testing using CHOP's clinical expertise and Labcorp's scientific and commercialization capabilities.

What benefits might investors expect from Labcorp's (LH) collaboration with CHOP?

The partnership could broaden Labcorp's pediatric testing portfolio and commercial reach, potentially supporting future diagnostic revenue growth. According to Labcorp, combining clinical expertise with national lab infrastructure aims to accelerate test commercialization and patient access.